In a phase II clinical trial involving patients with MDS and TP53 mutations (Clinical trial NCT03745716), APR-246 demonstrated a complete remission (CR) rate of 30%, signifying its dual role in correcting p53 defects and mitigating immune escape mechanisms 44. Here, TP53 is linked to myelodysplastic syndrome.